NYU Langone Study Reveals Pancreatic Cancer Cells' Genetic Shifts Fuel Treatment Resistance

  • NYU Langone researchers analyzed 443,451 single cells from 62 tumors of 56 pancreatic ductal adenocarcinoma patients.
  • Study identified diverse clones within tumors, with some evolving to resist therapy and others spreading rapidly.
  • MYC gene activity increased in aggressive tumor cell populations, while TIGIT gene activity helped cells evade immune detection.
  • Blocking MYC activity reverted cells to less aggressive forms and exposed them to more immune cells.
  • Research suggests single-cell clonal analysis provides better insights into complex cancer evolution.

This study challenges traditional bulk-cell analysis methods, highlighting the importance of clonal diversity in pancreatic cancer treatment resistance. The findings could reshape how researchers approach targeted therapies and immune treatments for this aggressive cancer type. NYU Langone's research positions it at the forefront of precision medicine advancements in oncology.

Therapeutic Targeting
How MYC and TIGIT inhibitors will perform in clinical trials for pancreatic cancer.
Diagnostic Advances
The pace at which single-cell clonal analysis becomes standard in cancer diagnosis.
Immune Evasion
Whether understanding TIGIT and PD1 interactions will improve immunotherapy effectiveness.